ArticleFrontiers in oncology2024

Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis.

Zhengzheng Xia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.